Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Last Updated: 2026

GlycoMimetics

Rank#10233

Market Cap10.13M

CountryUnited States

Summary

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

History

GlycoMimetics was founded in 2002 to develop specialty pharmaceuticals focusing on carbohydrate research to address the serious medical need for innovative therapies to treat orphan indications. GlycoMimetics has since advanced to clinical-stages and is developing its lead candidate, Uplyso, for the treatment of transfusion-dependent ?-thalassemia, a genetic disorder that affects red blood cell production.

Mission

GlycoMimetics mission is to discover and develop innovative therapeutics that mimic carbohydrates to alter disease progression and accelerate patient recovery.

Vision

GlycoMimetics vision is to be a preeminent leader in the development of carbohydrate-based drugs that improve patients’ lives.

References

https://in.investing.com/equities/glycomimetc

https://finance.yahoo.com/quote/GLYC/profile?p=GLYC

https://www.crunchbase.com/organization/glycomimetics

https://companiesmarketcap.com/

https://www.glycomimetics.com

Leadership team

Mr. Harout Semerjian (CEO, Pres & Director)

Dr. John L. Magnani Ph.D. (Sr. VP of Research & Chief Scientific Officer)

Mr. Brian M. Hahn (Sr. VP & CFO)

Products / Services

Biotechnology, Health Care, Therapeutics

Number of Employees

50 - 100

Address

Gaithersburg, Maryland, United States

Established

2003-01-01

Company Registration

SEC CIK number: 0001253689

Traded as

GLYC

Website

https://www.glycomimetics.com

Social Media

Last Updated: 2026

Get Your Own Businessabc AI Visibility ID

Boost AI visibility, credibility, and discoverability

Learn More

Last Updated: 2026

GlycoMimetics

Rank#10233

Market Cap10.13M

CountryUnited States

Summary

History

Mission

GlycoMimetics mission is to discover and develop innovative therapeutics that mimic carbohydrates to alter disease progression and accelerate patient recovery.

Vision

GlycoMimetics vision is to be a preeminent leader in the development of carbohydrate-based drugs that improve patients’ lives.

References

https://in.investing.com/equities/glycomimetc

https://finance.yahoo.com/quote/GLYC/profile?p=GLYC

https://www.crunchbase.com/organization/glycomimetics

https://companiesmarketcap.com/

https://www.glycomimetics.com

Leadership team

Mr. Harout Semerjian (CEO, Pres & Director)

Dr. John L. Magnani Ph.D. (Sr. VP of Research & Chief Scientific Officer)

Mr. Brian M. Hahn (Sr. VP & CFO)